Dang Yuan, Wang Ying-Chao, Huang Qiao-Jia
Department of Experimental Medicine, Fuzhou General Hospital (Dongfang Hospital), Fuzhou, China E-mail :
Asian Pac J Cancer Prev. 2014;15(19):8033-9.
Gastric cancer is the second after lung cause of cancer-related mortality in the world. Early detection and treatment can lead to a long survival time. Recently microarrays and next generation sequencing (NGS) have become very useful tools of comprehensive research into gastric cancer, facilitating the identification of treatment targets and personalized treatments. However, there are numerous challenges from cancer target discovery to practical clinical benefits. Although there are many biomarkers and target agents, only a minority of patients are tested and treated accordingly. Microarray technology with maturity was established more than 10 years ago, and has been widely used in the study of functional genomics, systems biology, and genomes in medicine. Second generation sequencing technology is more recent, but development is very fast, and it has been applied to the genome, including sequencing and epigenetics and many aspects of functional genomics. Here we review insights gained from these studies regarding the technology of microarray and NGS, how to elucidate the molecular basis of gastric cancer and identify potential therapeutic targets, and how to analyse candidate genes. We also discuss the challenges and future directions of such efforts.
胃癌是全球癌症相关死亡率仅次于肺癌的第二大病因。早期检测和治疗可带来较长的生存期。近年来，微阵列和新一代测序（NGS）已成为胃癌综合研究的非常有用的工具，有助于确定治疗靶点和个性化治疗。然而，从癌症靶点发现到实际临床获益存在众多挑战。尽管有许多生物标志物和靶向药物，但只有少数患者接受相应检测和治疗。成熟的微阵列技术在十多年前就已建立，并已广泛应用于功能基因组学、系统生物学和医学基因组研究。第二代测序技术较新，但发展非常迅速，已应用于基因组，包括测序、表观遗传学以及功能基因组学的许多方面。在此，我们综述了从这些研究中获得的关于微阵列和NGS技术的见解，如何阐明胃癌的分子基础并确定潜在治疗靶点，以及如何分析候选基因。我们还讨论了这些努力面临的挑战和未来方向。
